Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors

NCT ID NCT07703878

Not yet recruiting Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that have worsened after standard treatments or who cannot take those treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental oral drug called GS-1206
What this could lead to: If successful, this could lead to a new treatment option for people with certain solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial focused on safety, so the drug may not shrink tumors or improve survival. Side effects are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.